Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Baxter invests $100M in sterile fill/finish manufacturing facility expansion » 09:03
11/11/21
11/11
09:03
11/11/21
09:03
BAX

Baxter

$79.01 /

+1.31 (+1.69%)

Baxter announced an…

Baxter announced an approximately $100M expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany. This facility is operated by BioPharma Solutions, or BPS, a business unit of Baxter that specializes in partnering with leading pharmaceutical and biotech companies on the development and contract manufacturing of drug product for parenteral pharmaceuticals. Construction on the new manufacturing building is expected to begin in 2022 and be completed in 2024. This strategic investment will expand the BPS manufacturing footprint and add equipment designed to help products achieve stability and improved shelf life through lyophilization. Construction will also add an aseptic syringe filling line, enabling BPS to meet the growing demand for this delivery platform in both Europe and the United States. Pre-filled syringes can enhance efficiency and ease-of-use for clinicians and have potential to minimize microbial contamination and reduce medication dosing errors during medication preparation, which are key considerations for patient safety.

ShowHide Related Items >><<
BAX Baxter
$79.01 /

+1.31 (+1.69%)

BAX Baxter
$79.01 /

+1.31 (+1.69%)

11/05/21 Stifel
Hill-Rom downgraded to Hold from Buy at Stifel
10/28/21 Piper Sandler
Piper Sandler keeps a Neutral rating on Baxter following quarterly results
09/21/21 Raymond James
Baxter resumed with an Outperform at Raymond James
09/19/21 Morgan Stanley
Hill-Rom downgraded to Equal Weight from Overweight at Morgan Stanley
BAX Baxter
$79.01 /

+1.31 (+1.69%)

BAX Baxter
$79.01 /

+1.31 (+1.69%)

BAX Baxter
$79.01 /

+1.31 (+1.69%)

BAX Baxter
$79.01 /

+1.31 (+1.69%)

Conference/Events
Credit Suisse to hold a virtual conference » 04:55
11/11/21
11/11
04:55
11/11/21
04:55
USPH

U.S. Physical Therapy

$103.41 /

-0.59 (-0.57%)

, BAX

Baxter

$79.01 /

+1.31 (+1.69%)

, UTHR

United Therapeutics

$202.52 /

+3.57 (+1.79%)

, VRDN

Viridian Therapeutics

$18.51 /

+0.39 (+2.15%)

, ALXO

ALX Oncology

$42.35 /

+1.72 (+4.23%)

, CRSP

Crispr Therapeutics

$87.53 /

-3.71 (-4.07%)

, EHC

Encompass Health

$64.93 /

+0.89 (+1.39%)

, EFTR

eFfector Therapeutics

$10.22 /

-0.57 (-5.28%)

, CADL

Candel Therapeutics

$10.88 /

-0.02 (-0.18%)

, CBAY

CymaBay

$4.27 /

-0.02 (-0.47%)

, HSKA

Heska

$184.23 /

-3.555 (-1.89%)

, VYGR

Voyager Therapeutics

$3.53 /

-0.095 (-2.62%)

, CYT

Cyteir Therapeutics

$15.85 /

-0.295 (-1.83%)

, CYH

Community Health

$14.74 /

+0.04 (+0.27%)

30th Annual Virtual…

30th Annual Virtual Healthcare Conference to be held on November 8-11. Webcast Link

ShowHide Related Items >><<
VYGR Voyager Therapeutics
$3.53 /

-0.095 (-2.62%)

VRDN Viridian Therapeutics
$18.51 /

+0.39 (+2.15%)

UTHR United Therapeutics
$202.52 /

+3.57 (+1.79%)

USPH U.S. Physical Therapy
$103.41 /

-0.59 (-0.57%)

HSKA Heska
$184.23 /

-3.555 (-1.89%)

EHC Encompass Health
$64.93 /

+0.89 (+1.39%)

EFTR eFfector Therapeutics
$10.22 /

-0.57 (-5.28%)

CYT Cyteir Therapeutics
$15.85 /

-0.295 (-1.83%)

CYH Community Health
$14.74 /

+0.04 (+0.27%)

CRSP Crispr Therapeutics
$87.53 /

-3.71 (-4.07%)

CBAY CymaBay
$4.27 /

-0.02 (-0.47%)

CADL Candel Therapeutics
$10.88 /

-0.02 (-0.18%)

BAX Baxter
$79.01 /

+1.31 (+1.69%)

ALXO ALX Oncology
$42.35 /

+1.72 (+4.23%)

USPH U.S. Physical Therapy
$103.41 /

-0.59 (-0.57%)

08/06/21 Barrington
U.S. Physical Therapy price target raised to $139 from $130 at Barrington
05/07/21 Barrington
U.S. Physical Therapy upgraded to Outperform from Market Perform at Barrington
05/03/21 Jefferies
U.S. Physical Therapy upgraded to Buy from Hold at Jefferies
02/26/21 Barrington
U.S. Physical Therapy downgraded to Market Perform from Outperform at Barrington
BAX Baxter
$79.01 /

+1.31 (+1.69%)

11/05/21 Stifel
Hill-Rom downgraded to Hold from Buy at Stifel
10/28/21 Piper Sandler
Piper Sandler keeps a Neutral rating on Baxter following quarterly results
09/21/21 Raymond James
Baxter resumed with an Outperform at Raymond James
09/19/21 Morgan Stanley
Hill-Rom downgraded to Equal Weight from Overweight at Morgan Stanley
UTHR United Therapeutics
$202.52 /

+3.57 (+1.79%)

11/08/21 Needham
Liquidia Technologies price target raised to $8 from $5 at Needham
07/14/21
Fly Intel: Top five analyst upgrades
07/14/21 Argus
United Therapeutics upgraded to Buy from Hold at Argus
07/14/21 Argus
United Therapeutics upgraded to Buy from Hold at Argus
VRDN Viridian Therapeutics
$18.51 /

+0.39 (+2.15%)

11/05/21 JMP Securities
Viridian Therapeutics price target lowered to $36 from $44 at JMP Securities
10/12/21 Evercore ISI
Evercore starts Viridian at Outperform on thyroid eye disease opportunity
10/12/21 Evercore ISI
Viridian Therapeutics initiated with an Outperform at Evercore ISI
01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
ALXO ALX Oncology
$42.35 /

+1.72 (+4.23%)

11/09/21 Piper Sandler
ALX Oncology price target lowered to $85 from $97 at Piper Sandler
11/09/21 H.C. Wainwright
H.C. Wainwright says ALX Oncology selloff on ASPEN-01 data an entry opportunity
11/04/21 Piper Sandler
ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler
09/29/21 Stifel
ALX Oncology initiated with a Buy at Stifel
CRSP Crispr Therapeutics
$87.53 /

-3.71 (-4.07%)

11/08/21 Goldman Sachs
Bluebird Bio downgraded to Sell from Neutral at Goldman Sachs
11/04/21 Raymond James
ASH abstracts justify Crispr Therapeutics concerns, says Raymond James
11/04/21 Oppenheimer
Crispr Therapeutics price target lowered to $172 from $185 at Oppenheimer
10/19/21 SVB Leerink
Crispr Therapeutics initiated with an Outperform at SVB Leerink
EHC Encompass Health
$64.93 /

+0.89 (+1.39%)

11/03/21 Mizuho
Encompass Health price target lowered to $80 from $94 at Mizuho
11/01/21 BMO Capital
Encompass Health price target lowered to $75 from $102 at BMO Capital
10/29/21 Deutsche Bank
Encompass Health price target lowered to $95 from $110 at Deutsche Bank
10/13/21 Truist
Encompass Health price target lowered to $88 from $100 at Truist
EFTR eFfector Therapeutics
$10.22 /

-0.57 (-5.28%)

11/08/21 Stifel
eFfector Therapeutics upgraded to Buy at Stifel on NSCLC optimism
11/08/21 Stifel
eFfector Therapeutics upgraded to Buy from Hold at Stifel
10/12/21 Credit Suisse
eFfector Therapeutics initiated with an Outperform at Credit Suisse
10/04/21 Mizuho
eFfector Therapeutics initiated with a Buy at Mizuho
CADL Candel Therapeutics
$10.88 /

-0.02 (-0.18%)

08/23/21 UBS
Candel Therapeutics initiated with a Buy at UBS
08/23/21 Jefferies
Candel Therapeutics initiated with a Buy at Jefferies
08/23/21 Credit Suisse
Candel Therapeutics initiated with an Outperform at Credit Suisse
CBAY CymaBay
$4.27 /

-0.02 (-0.47%)

11/10/21 Piper Sandler
Piper Sandler says buyer of CymaBay at low valuation
08/18/21 B. Riley
CymaBay price target lowered to $10 from $13 at B. Riley
08/03/21 H.C. Wainwright
CymaBay price target lowered to $12 from $13 at H.C. Wainwright
08/02/21 Piper Sandler
CymaBay agreement removes 'key pressure point,' says Piper Sandler
HSKA Heska
$184.23 /

-3.555 (-1.89%)

10/26/21 Alliance Global Partners
Alliance Global reiterates Buy on Heska, says short report lacks credibility
08/04/21 Alliance Global Partners
Heska price target raised to $310 from $240 at Alliance Global Partners
08/04/21 Piper Sandler
Heska price target raised to $305 from $240 at Piper Sandler
07/12/21 Guggenheim
Heska upgraded to Buy from Neutral at Guggenheim
VYGR Voyager Therapeutics
$3.53 /

-0.095 (-2.62%)

11/02/21 Chardan
Voyager Therapeutics price target lowered to $4 from $5.50 at Chardan
10/07/21 Baird
Voyager Therapeutics upgraded to Outperform from Neutral at Baird
10/06/21 Wells Fargo
Voyager platform validated by Pfizer agreement, says Wells Fargo
09/20/21 Benchmark
Sale of Voyager more likely than out-licensing, says Benchmark
CYT Cyteir Therapeutics
$15.85 /

-0.295 (-1.83%)

07/13/21 JPMorgan
Cyteir Therapeutics initiated with an Overweight at JPMorgan
07/13/21 BofA
BofA starts Cyteir Therapeutics at Buy with $23 price target
07/13/21 Wedbush
Cyteir Therapeutics initiated with an Outperform at Wedbush
07/13/21 Morgan Stanley
Cyteir Therapeutics initiated with an Overweight at Morgan Stanley
CYH Community Health
$14.74 /

+0.04 (+0.27%)

10/13/21 Truist
Community Health price target lowered to $12 from $14 at Truist
09/23/21 UBS
Community Health initiated with a Neutral at UBS
09/23/21 UBS
Community Health initiated with a Neutral at UBS
08/23/21 Truist
Community Health price target lowered to $14 from $17 at Truist
VYGR Voyager Therapeutics
$3.53 /

-0.095 (-2.62%)

VRDN Viridian Therapeutics
$18.51 /

+0.39 (+2.15%)

UTHR United Therapeutics
$202.52 /

+3.57 (+1.79%)

USPH U.S. Physical Therapy
$103.41 /

-0.59 (-0.57%)

HSKA Heska
$184.23 /

-3.555 (-1.89%)

EHC Encompass Health
$64.93 /

+0.89 (+1.39%)

EFTR eFfector Therapeutics
$10.22 /

-0.57 (-5.28%)

CYH Community Health
$14.74 /

+0.04 (+0.27%)

CRSP Crispr Therapeutics
$87.53 /

-3.71 (-4.07%)

CBAY CymaBay
$4.27 /

-0.02 (-0.47%)

CADL Candel Therapeutics
$10.88 /

-0.02 (-0.18%)

BAX Baxter
$79.01 /

+1.31 (+1.69%)

ALXO ALX Oncology
$42.35 /

+1.72 (+4.23%)

  • 21
    Sep
  • 27
    Jul
  • 18
    Jun
  • 03
    Mar
  • 13
    Jan
  • 10
    Dec
HSKA Heska
$184.23 /

-3.555 (-1.89%)

CYH Community Health
$14.74 /

+0.04 (+0.27%)

BAX Baxter
$79.01 /

+1.31 (+1.69%)

VRDN Viridian Therapeutics
$18.51 /

+0.39 (+2.15%)

UTHR United Therapeutics
$202.52 /

+3.57 (+1.79%)

HSKA Heska
$184.23 /

-3.555 (-1.89%)

EHC Encompass Health
$64.93 /

+0.89 (+1.39%)

EFTR eFfector Therapeutics
$10.22 /

-0.57 (-5.28%)

CYT Cyteir Therapeutics
$15.85 /

-0.295 (-1.83%)

CYH Community Health
$14.74 /

+0.04 (+0.27%)

CRSP Crispr Therapeutics
$87.53 /

-3.71 (-4.07%)

CADL Candel Therapeutics
$10.88 /

-0.02 (-0.18%)

BAX Baxter
$79.01 /

+1.31 (+1.69%)

ALXO ALX Oncology
$42.35 /

+1.72 (+4.23%)

VYGR Voyager Therapeutics
$3.53 /

-0.095 (-2.62%)

VRDN Viridian Therapeutics
$18.51 /

+0.39 (+2.15%)

EHC Encompass Health
$64.93 /

+0.89 (+1.39%)

CYH Community Health
$14.74 /

+0.04 (+0.27%)

CRSP Crispr Therapeutics
$87.53 /

-3.71 (-4.07%)

BAX Baxter
$79.01 /

+1.31 (+1.69%)

Conference/Events
Credit Suisse to hold a virtual conference » 04:55
11/10/21
11/10
04:55
11/10/21
04:55
USPH

U.S. Physical Therapy

$103.83 /

-1.55 (-1.47%)

, BAX

Baxter

$77.70 /

-1.04 (-1.32%)

, UTHR

United Therapeutics

$198.97 /

-3.39 (-1.68%)

, VRDN

Viridian Therapeutics

$18.10 /

-0.53 (-2.84%)

, ALXO

ALX Oncology

$40.81 /

-11.615 (-22.16%)

, CRSP

Crispr Therapeutics

$91.26 /

-2.95 (-3.13%)

, EHC

Encompass Health

$64.05 /

-1.255 (-1.92%)

, EFTR

eFfector Therapeutics

$10.79 /

-0.32 (-2.88%)

, CADL

Candel Therapeutics

$10.95 /

-0.485 (-4.24%)

, CBAY

CymaBay

$4.30 /

+0.015 (+0.35%)

, HSKA

Heska

$188.94 /

-7.3 (-3.72%)

, VYGR

Voyager Therapeutics

$3.62 /

-0.02 (-0.55%)

, CYT

Cyteir Therapeutics

$16.14 /

-0.66 (-3.93%)

, CYH

Community Health

$14.70 /

+0.34 (+2.37%)

30th Annual Virtual…

30th Annual Virtual Healthcare Conference to be held on November 8-11. Webcast Link

ShowHide Related Items >><<
VYGR Voyager Therapeutics
$3.62 /

-0.02 (-0.55%)

VRDN Viridian Therapeutics
$18.10 /

-0.53 (-2.84%)

UTHR United Therapeutics
$198.97 /

-3.39 (-1.68%)

USPH U.S. Physical Therapy
$103.83 /

-1.55 (-1.47%)

HSKA Heska
$188.94 /

-7.3 (-3.72%)

EHC Encompass Health
$64.05 /

-1.255 (-1.92%)

EFTR eFfector Therapeutics
$10.79 /

-0.32 (-2.88%)

CYT Cyteir Therapeutics
$16.14 /

-0.66 (-3.93%)

CYH Community Health
$14.70 /

+0.34 (+2.37%)

CRSP Crispr Therapeutics
$91.26 /

-2.95 (-3.13%)

CBAY CymaBay
$4.30 /

+0.015 (+0.35%)

CADL Candel Therapeutics
$10.95 /

-0.485 (-4.24%)

BAX Baxter
$77.70 /

-1.04 (-1.32%)

ALXO ALX Oncology
$40.81 /

-11.615 (-22.16%)

USPH U.S. Physical Therapy
$103.83 /

-1.55 (-1.47%)

08/06/21 Barrington
U.S. Physical Therapy price target raised to $139 from $130 at Barrington
05/07/21 Barrington
U.S. Physical Therapy upgraded to Outperform from Market Perform at Barrington
05/03/21 Jefferies
U.S. Physical Therapy upgraded to Buy from Hold at Jefferies
02/26/21 Barrington
U.S. Physical Therapy downgraded to Market Perform from Outperform at Barrington
BAX Baxter
$77.70 /

-1.04 (-1.32%)

11/05/21 Stifel
Hill-Rom downgraded to Hold from Buy at Stifel
10/28/21 Piper Sandler
Piper Sandler keeps a Neutral rating on Baxter following quarterly results
09/21/21 Raymond James
Baxter resumed with an Outperform at Raymond James
09/19/21 Morgan Stanley
Hill-Rom downgraded to Equal Weight from Overweight at Morgan Stanley
UTHR United Therapeutics
$198.97 /

-3.39 (-1.68%)

11/08/21 Needham
Liquidia Technologies price target raised to $8 from $5 at Needham
07/14/21
Fly Intel: Top five analyst upgrades
07/14/21 Argus
United Therapeutics upgraded to Buy from Hold at Argus
07/14/21 Argus
United Therapeutics upgraded to Buy from Hold at Argus
VRDN Viridian Therapeutics
$18.10 /

-0.53 (-2.84%)

11/05/21 JMP Securities
Viridian Therapeutics price target lowered to $36 from $44 at JMP Securities
10/12/21 Evercore ISI
Evercore starts Viridian at Outperform on thyroid eye disease opportunity
10/12/21 Evercore ISI
Viridian Therapeutics initiated with an Outperform at Evercore ISI
01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
ALXO ALX Oncology
$40.81 /

-11.615 (-22.16%)

11/09/21 Piper Sandler
ALX Oncology price target lowered to $85 from $97 at Piper Sandler
11/09/21 H.C. Wainwright
H.C. Wainwright says ALX Oncology selloff on ASPEN-01 data an entry opportunity
11/04/21 Piper Sandler
ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler
09/29/21 Stifel
ALX Oncology initiated with a Buy at Stifel
CRSP Crispr Therapeutics
$91.26 /

-2.95 (-3.13%)

11/08/21 Goldman Sachs
Bluebird Bio downgraded to Sell from Neutral at Goldman Sachs
11/04/21 Raymond James
ASH abstracts justify Crispr Therapeutics concerns, says Raymond James
11/04/21 Oppenheimer
Crispr Therapeutics price target lowered to $172 from $185 at Oppenheimer
10/19/21 SVB Leerink
Crispr Therapeutics initiated with an Outperform at SVB Leerink
EHC Encompass Health
$64.05 /

-1.255 (-1.92%)

11/03/21 Mizuho
Encompass Health price target lowered to $80 from $94 at Mizuho
11/01/21 BMO Capital
Encompass Health price target lowered to $75 from $102 at BMO Capital
10/29/21 Deutsche Bank
Encompass Health price target lowered to $95 from $110 at Deutsche Bank
10/13/21 Truist
Encompass Health price target lowered to $88 from $100 at Truist
EFTR eFfector Therapeutics
$10.79 /

-0.32 (-2.88%)

11/08/21 Stifel
eFfector Therapeutics upgraded to Buy at Stifel on NSCLC optimism
11/08/21 Stifel
eFfector Therapeutics upgraded to Buy from Hold at Stifel
10/12/21 Credit Suisse
eFfector Therapeutics initiated with an Outperform at Credit Suisse
10/04/21 Mizuho
eFfector Therapeutics initiated with a Buy at Mizuho
CADL Candel Therapeutics
$10.95 /

-0.485 (-4.24%)

08/23/21 UBS
Candel Therapeutics initiated with a Buy at UBS
08/23/21 Jefferies
Candel Therapeutics initiated with a Buy at Jefferies
08/23/21 Credit Suisse
Candel Therapeutics initiated with an Outperform at Credit Suisse
CBAY CymaBay
$4.30 /

+0.015 (+0.35%)

08/18/21 B. Riley
CymaBay price target lowered to $10 from $13 at B. Riley
08/03/21 H.C. Wainwright
CymaBay price target lowered to $12 from $13 at H.C. Wainwright
08/02/21 Piper Sandler
CymaBay agreement removes 'key pressure point,' says Piper Sandler
06/21/21 Piper Sandler
Piper radar 'locked' on CymaBay EASL poster presentations on June 23
HSKA Heska
$188.94 /

-7.3 (-3.72%)

10/26/21 Alliance Global Partners
Alliance Global reiterates Buy on Heska, says short report lacks credibility
08/04/21 Alliance Global Partners
Heska price target raised to $310 from $240 at Alliance Global Partners
08/04/21 Piper Sandler
Heska price target raised to $305 from $240 at Piper Sandler
07/12/21 Guggenheim
Heska upgraded to Buy from Neutral at Guggenheim
VYGR Voyager Therapeutics
$3.62 /

-0.02 (-0.55%)

11/02/21 Chardan
Voyager Therapeutics price target lowered to $4 from $5.50 at Chardan
10/07/21 Baird
Voyager Therapeutics upgraded to Outperform from Neutral at Baird
10/06/21 Wells Fargo
Voyager platform validated by Pfizer agreement, says Wells Fargo
09/20/21 Benchmark
Sale of Voyager more likely than out-licensing, says Benchmark
CYT Cyteir Therapeutics
$16.14 /

-0.66 (-3.93%)

07/13/21 JPMorgan
Cyteir Therapeutics initiated with an Overweight at JPMorgan
07/13/21 BofA
BofA starts Cyteir Therapeutics at Buy with $23 price target
07/13/21 Wedbush
Cyteir Therapeutics initiated with an Outperform at Wedbush
07/13/21 Morgan Stanley
Cyteir Therapeutics initiated with an Overweight at Morgan Stanley
CYH Community Health
$14.70 /

+0.34 (+2.37%)

10/13/21 Truist
Community Health price target lowered to $12 from $14 at Truist
09/23/21 UBS
Community Health initiated with a Neutral at UBS
09/23/21 UBS
Community Health initiated with a Neutral at UBS
08/23/21 Truist
Community Health price target lowered to $14 from $17 at Truist
VYGR Voyager Therapeutics
$3.62 /

-0.02 (-0.55%)

VRDN Viridian Therapeutics
$18.10 /

-0.53 (-2.84%)

UTHR United Therapeutics
$198.97 /

-3.39 (-1.68%)

USPH U.S. Physical Therapy
$103.83 /

-1.55 (-1.47%)

HSKA Heska
$188.94 /

-7.3 (-3.72%)

EHC Encompass Health
$64.05 /

-1.255 (-1.92%)

EFTR eFfector Therapeutics
$10.79 /

-0.32 (-2.88%)

CYH Community Health
$14.70 /

+0.34 (+2.37%)

CRSP Crispr Therapeutics
$91.26 /

-2.95 (-3.13%)

CBAY CymaBay
$4.30 /

+0.015 (+0.35%)

CADL Candel Therapeutics
$10.95 /

-0.485 (-4.24%)

BAX Baxter
$77.70 /

-1.04 (-1.32%)

ALXO ALX Oncology
$40.81 /

-11.615 (-22.16%)

  • 21
    Sep
  • 27
    Jul
  • 18
    Jun
  • 03
    Mar
  • 13
    Jan
  • 10
    Dec
HSKA Heska
$188.94 /

-7.3 (-3.72%)

CYH Community Health
$14.70 /

+0.34 (+2.37%)

BAX Baxter
$77.70 /

-1.04 (-1.32%)

VRDN Viridian Therapeutics
$18.10 /

-0.53 (-2.84%)

UTHR United Therapeutics
$198.97 /

-3.39 (-1.68%)

HSKA Heska
$188.94 /

-7.3 (-3.72%)

EHC Encompass Health
$64.05 /

-1.255 (-1.92%)

EFTR eFfector Therapeutics
$10.79 /

-0.32 (-2.88%)

CYT Cyteir Therapeutics
$16.14 /

-0.66 (-3.93%)

CYH Community Health
$14.70 /

+0.34 (+2.37%)

CRSP Crispr Therapeutics
$91.26 /

-2.95 (-3.13%)

CADL Candel Therapeutics
$10.95 /

-0.485 (-4.24%)

BAX Baxter
$77.70 /

-1.04 (-1.32%)

ALXO ALX Oncology
$40.81 /

-11.615 (-22.16%)

VYGR Voyager Therapeutics
$3.62 /

-0.02 (-0.55%)

VRDN Viridian Therapeutics
$18.10 /

-0.53 (-2.84%)

EHC Encompass Health
$64.05 /

-1.255 (-1.92%)

CYH Community Health
$14.70 /

+0.34 (+2.37%)

CRSP Crispr Therapeutics
$91.26 /

-2.95 (-3.13%)

BAX Baxter
$77.70 /

-1.04 (-1.32%)

Conference/Events
Credit Suisse to hold a virtual conference » 04:55
11/09/21
11/09
04:55
11/09/21
04:55
USPH

U.S. Physical Therapy

$105.78 /

-3.63 (-3.32%)

, BAX

Baxter

$78.75 /

+0.72 (+0.92%)

, UTHR

United Therapeutics

$202.19 /

-0.18 (-0.09%)

, VRDN

Viridian Therapeutics

$18.50 /

-0.5 (-2.63%)

, ALXO

ALX Oncology

$52.16 /

+1.32 (+2.60%)

, CRSP

Crispr Therapeutics

$94.21 /

+3.9 (+4.32%)

, EHC

Encompass Health

$65.39 /

+0.445 (+0.69%)

, EFTR

eFfector Therapeutics

$11.06 /

+0.68 (+6.55%)

, CADL

Candel Therapeutics

$11.44 /

+0.725 (+6.77%)

, CBAY

CymaBay

$4.26 /

-0.13 (-2.96%)

, HSKA

Heska

$195.37 /

+3.035 (+1.58%)

, VYGR

Voyager Therapeutics

$3.64 /

-0.16 (-4.21%)

, CYT

Cyteir Therapeutics

$16.80 /

+0.05 (+0.30%)

, CYH

Community Health

$14.36 /

-0.04 (-0.28%)

30th Annual Virtual…

30th Annual Virtual Healthcare Conference to be held on November 8-11. Webcast Link

ShowHide Related Items >><<
VYGR Voyager Therapeutics
$3.64 /

-0.16 (-4.21%)

VRDN Viridian Therapeutics
$18.50 /

-0.5 (-2.63%)

UTHR United Therapeutics
$202.19 /

-0.18 (-0.09%)

USPH U.S. Physical Therapy
$105.78 /

-3.63 (-3.32%)

HSKA Heska
$195.37 /

+3.035 (+1.58%)

EHC Encompass Health
$65.39 /

+0.445 (+0.69%)

EFTR eFfector Therapeutics
$11.06 /

+0.68 (+6.55%)

CYT Cyteir Therapeutics
$16.80 /

+0.05 (+0.30%)

CYH Community Health
$14.36 /

-0.04 (-0.28%)

CRSP Crispr Therapeutics
$94.21 /

+3.9 (+4.32%)

CBAY CymaBay
$4.26 /

-0.13 (-2.96%)

CADL Candel Therapeutics
$11.44 /

+0.725 (+6.77%)

BAX Baxter
$78.75 /

+0.72 (+0.92%)

ALXO ALX Oncology
$52.16 /

+1.32 (+2.60%)

USPH U.S. Physical Therapy
$105.78 /

-3.63 (-3.32%)

08/06/21 Barrington
U.S. Physical Therapy price target raised to $139 from $130 at Barrington
05/07/21 Barrington
U.S. Physical Therapy upgraded to Outperform from Market Perform at Barrington
05/03/21 Jefferies
U.S. Physical Therapy upgraded to Buy from Hold at Jefferies
02/26/21 Barrington
U.S. Physical Therapy downgraded to Market Perform from Outperform at Barrington
BAX Baxter
$78.75 /

+0.72 (+0.92%)

11/05/21 Stifel
Hill-Rom downgraded to Hold from Buy at Stifel
10/28/21 Piper Sandler
Piper Sandler keeps a Neutral rating on Baxter following quarterly results
09/21/21 Raymond James
Baxter resumed with an Outperform at Raymond James
09/19/21 Morgan Stanley
Hill-Rom downgraded to Equal Weight from Overweight at Morgan Stanley
UTHR United Therapeutics
$202.19 /

-0.18 (-0.09%)

11/08/21 Needham
Liquidia Technologies price target raised to $8 from $5 at Needham
07/14/21
Fly Intel: Top five analyst upgrades
07/14/21 Argus
United Therapeutics upgraded to Buy from Hold at Argus
07/14/21 Argus
United Therapeutics upgraded to Buy from Hold at Argus
VRDN Viridian Therapeutics
$18.50 /

-0.5 (-2.63%)

11/05/21 JMP Securities
Viridian Therapeutics price target lowered to $36 from $44 at JMP Securities
10/12/21 Evercore ISI
Evercore starts Viridian at Outperform on thyroid eye disease opportunity
10/12/21 Evercore ISI
Viridian Therapeutics initiated with an Outperform at Evercore ISI
01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
ALXO ALX Oncology
$52.16 /

+1.32 (+2.60%)

11/04/21 Piper Sandler
ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler
09/29/21 Stifel
ALX Oncology initiated with a Buy at Stifel
07/05/21 Piper Sandler
ALX Oncology update for ALX148 'incrementally positive,' says Piper Sandler
05/04/21 Credit Suisse
ALX Oncology assumed with an Outperform at Credit Suisse
CRSP Crispr Therapeutics
$94.21 /

+3.9 (+4.32%)

11/08/21 Goldman Sachs
Bluebird Bio downgraded to Sell from Neutral at Goldman Sachs
11/04/21 Raymond James
ASH abstracts justify Crispr Therapeutics concerns, says Raymond James
11/04/21 Oppenheimer
Crispr Therapeutics price target lowered to $172 from $185 at Oppenheimer
10/19/21 SVB Leerink
Crispr Therapeutics initiated with an Outperform at SVB Leerink
EHC Encompass Health
$65.39 /

+0.445 (+0.69%)

11/03/21 Mizuho
Encompass Health price target lowered to $80 from $94 at Mizuho
11/01/21 BMO Capital
Encompass Health price target lowered to $75 from $102 at BMO Capital
10/29/21 Deutsche Bank
Encompass Health price target lowered to $95 from $110 at Deutsche Bank
10/13/21 Truist
Encompass Health price target lowered to $88 from $100 at Truist
EFTR eFfector Therapeutics
$11.06 /

+0.68 (+6.55%)

11/08/21 Stifel
eFfector Therapeutics upgraded to Buy at Stifel on NSCLC optimism
11/08/21 Stifel
eFfector Therapeutics upgraded to Buy from Hold at Stifel
10/12/21 Credit Suisse
eFfector Therapeutics initiated with an Outperform at Credit Suisse
10/04/21 Mizuho
eFfector Therapeutics initiated with a Buy at Mizuho
CADL Candel Therapeutics
$11.44 /

+0.725 (+6.77%)

08/23/21 UBS
Candel Therapeutics initiated with a Buy at UBS
08/23/21 Jefferies
Candel Therapeutics initiated with a Buy at Jefferies
08/23/21 Credit Suisse
Candel Therapeutics initiated with an Outperform at Credit Suisse
CBAY CymaBay
$4.26 /

-0.13 (-2.96%)

08/18/21 B. Riley
CymaBay price target lowered to $10 from $13 at B. Riley
08/03/21 H.C. Wainwright
CymaBay price target lowered to $12 from $13 at H.C. Wainwright
08/02/21 Piper Sandler
CymaBay agreement removes 'key pressure point,' says Piper Sandler
06/21/21 Piper Sandler
Piper radar 'locked' on CymaBay EASL poster presentations on June 23
HSKA Heska
$195.37 /

+3.035 (+1.58%)

10/26/21 Alliance Global Partners
Alliance Global reiterates Buy on Heska, says short report lacks credibility
08/04/21 Alliance Global Partners
Heska price target raised to $310 from $240 at Alliance Global Partners
08/04/21 Piper Sandler
Heska price target raised to $305 from $240 at Piper Sandler
07/12/21 Guggenheim
Heska upgraded to Buy from Neutral at Guggenheim
VYGR Voyager Therapeutics
$3.64 /

-0.16 (-4.21%)

11/02/21 Chardan
Voyager Therapeutics price target lowered to $4 from $5.50 at Chardan
10/07/21 Baird
Voyager Therapeutics upgraded to Outperform from Neutral at Baird
10/06/21 Wells Fargo
Voyager platform validated by Pfizer agreement, says Wells Fargo
09/20/21 Benchmark
Sale of Voyager more likely than out-licensing, says Benchmark
CYT Cyteir Therapeutics
$16.80 /

+0.05 (+0.30%)

07/13/21 JPMorgan
Cyteir Therapeutics initiated with an Overweight at JPMorgan
07/13/21 BofA
BofA starts Cyteir Therapeutics at Buy with $23 price target
07/13/21 Wedbush
Cyteir Therapeutics initiated with an Outperform at Wedbush
07/13/21 Morgan Stanley
Cyteir Therapeutics initiated with an Overweight at Morgan Stanley
CYH Community Health
$14.36 /

-0.04 (-0.28%)

10/13/21 Truist
Community Health price target lowered to $12 from $14 at Truist
09/23/21 UBS
Community Health initiated with a Neutral at UBS
09/23/21 UBS
Community Health initiated with a Neutral at UBS
08/23/21 Truist
Community Health price target lowered to $14 from $17 at Truist
VYGR Voyager Therapeutics
$3.64 /

-0.16 (-4.21%)

VRDN Viridian Therapeutics
$18.50 /

-0.5 (-2.63%)

UTHR United Therapeutics
$202.19 /

-0.18 (-0.09%)

USPH U.S. Physical Therapy
$105.78 /

-3.63 (-3.32%)

HSKA Heska
$195.37 /

+3.035 (+1.58%)

EHC Encompass Health
$65.39 /

+0.445 (+0.69%)

EFTR eFfector Therapeutics
$11.06 /

+0.68 (+6.55%)

CYH Community Health
$14.36 /

-0.04 (-0.28%)

CRSP Crispr Therapeutics
$94.21 /

+3.9 (+4.32%)

CBAY CymaBay
$4.26 /

-0.13 (-2.96%)

CADL Candel Therapeutics
$11.44 /

+0.725 (+6.77%)

BAX Baxter
$78.75 /

+0.72 (+0.92%)

ALXO ALX Oncology
$52.16 /

+1.32 (+2.60%)

  • 21
    Sep
  • 27
    Jul
  • 18
    Jun
  • 03
    Mar
  • 13
    Jan
  • 10
    Dec
HSKA Heska
$195.37 /

+3.035 (+1.58%)

CYH Community Health
$14.36 /

-0.04 (-0.28%)

BAX Baxter
$78.75 /

+0.72 (+0.92%)

VRDN Viridian Therapeutics
$18.50 /

-0.5 (-2.63%)

UTHR United Therapeutics
$202.19 /

-0.18 (-0.09%)

HSKA Heska
$195.37 /

+3.035 (+1.58%)

EHC Encompass Health
$65.39 /

+0.445 (+0.69%)

EFTR eFfector Therapeutics
$11.06 /

+0.68 (+6.55%)

CYT Cyteir Therapeutics
$16.80 /

+0.05 (+0.30%)

CYH Community Health
$14.36 /

-0.04 (-0.28%)

CRSP Crispr Therapeutics
$94.21 /

+3.9 (+4.32%)

CADL Candel Therapeutics
$11.44 /

+0.725 (+6.77%)

BAX Baxter
$78.75 /

+0.72 (+0.92%)

ALXO ALX Oncology
$52.16 /

+1.32 (+2.60%)

VYGR Voyager Therapeutics
$3.64 /

-0.16 (-4.21%)

VRDN Viridian Therapeutics
$18.50 /

-0.5 (-2.63%)

EHC Encompass Health
$65.39 /

+0.445 (+0.69%)

CYH Community Health
$14.36 /

-0.04 (-0.28%)

CRSP Crispr Therapeutics
$94.21 /

+3.9 (+4.32%)

BAX Baxter
$78.75 /

+0.72 (+0.92%)

Conference/Events
Credit Suisse to hold a virtual conference » 10:59
11/08/21
11/08
10:59
11/08/21
10:59
USPH

U.S. Physical Therapy

$109.36 /

-0.05 (-0.05%)

, BAX

Baxter

$78.84 /

+0.81 (+1.04%)

, UTHR

United Therapeutics

$200.75 /

-1.62 (-0.80%)

, VRDN

Viridian Therapeutics

$18.12 /

-0.88 (-4.63%)

, ALXO

ALX Oncology

$55.06 /

+4.22 (+8.30%)

, CRSP

Crispr Therapeutics

$94.11 /

+3.8 (+4.21%)

, EHC

Encompass Health

$65.05 /

+0.105 (+0.16%)

, EFTR

eFfector Therapeutics

$10.98 /

+0.6 (+5.78%)

, CADL

Candel Therapeutics

$11.48 /

+0.77 (+7.19%)

, CBAY

CymaBay

$4.31 /

-0.08 (-1.82%)

, HSKA

Heska

$197.45 /

+5.115 (+2.66%)

, VYGR

Voyager Therapeutics

$3.72 /

-0.08 (-2.11%)

, CYT

Cyteir Therapeutics

$17.14 /

+0.39 (+2.33%)

, CYH

Community Health

$14.55 /

+0.15 (+1.04%)

30th Annual Virtual…

30th Annual Virtual Healthcare Conference to be held on November 8-11. Webcast Link

ShowHide Related Items >><<
VYGR Voyager Therapeutics
$3.72 /

-0.08 (-2.11%)

VRDN Viridian Therapeutics
$18.12 /

-0.88 (-4.63%)

UTHR United Therapeutics
$200.75 /

-1.62 (-0.80%)

USPH U.S. Physical Therapy
$109.36 /

-0.05 (-0.05%)

HSKA Heska
$197.45 /

+5.115 (+2.66%)

EHC Encompass Health
$65.05 /

+0.105 (+0.16%)

EFTR eFfector Therapeutics
$10.98 /

+0.6 (+5.78%)

CYT Cyteir Therapeutics
$17.14 /

+0.39 (+2.33%)

CYH Community Health
$14.55 /

+0.15 (+1.04%)

CRSP Crispr Therapeutics
$94.11 /

+3.8 (+4.21%)

CBAY CymaBay
$4.31 /

-0.08 (-1.82%)

CADL Candel Therapeutics
$11.48 /

+0.77 (+7.19%)

BAX Baxter
$78.84 /

+0.81 (+1.04%)

ALXO ALX Oncology
$55.06 /

+4.22 (+8.30%)

USPH U.S. Physical Therapy
$109.36 /

-0.05 (-0.05%)

08/06/21 Barrington
U.S. Physical Therapy price target raised to $139 from $130 at Barrington
05/07/21 Barrington
U.S. Physical Therapy upgraded to Outperform from Market Perform at Barrington
05/03/21 Jefferies
U.S. Physical Therapy upgraded to Buy from Hold at Jefferies
02/26/21 Barrington
U.S. Physical Therapy downgraded to Market Perform from Outperform at Barrington
BAX Baxter
$78.84 /

+0.81 (+1.04%)

11/05/21 Stifel
Hill-Rom downgraded to Hold from Buy at Stifel
10/28/21 Piper Sandler
Piper Sandler keeps a Neutral rating on Baxter following quarterly results
09/21/21 Raymond James
Baxter resumed with an Outperform at Raymond James
09/19/21 Morgan Stanley
Hill-Rom downgraded to Equal Weight from Overweight at Morgan Stanley
UTHR United Therapeutics
$200.75 /

-1.62 (-0.80%)

07/14/21
Fly Intel: Top five analyst upgrades
07/14/21 Argus
United Therapeutics upgraded to Buy from Hold at Argus
07/14/21 Argus
United Therapeutics upgraded to Buy from Hold at Argus
05/06/21 H.C. Wainwright
United Therapeutics price target raised to $248 from $195 at H.C. Wainwright
VRDN Viridian Therapeutics
$18.12 /

-0.88 (-4.63%)

11/05/21 JMP Securities
Viridian Therapeutics price target lowered to $36 from $44 at JMP Securities
10/12/21 Evercore ISI
Evercore starts Viridian at Outperform on thyroid eye disease opportunity
10/12/21 Evercore ISI
Viridian Therapeutics initiated with an Outperform at Evercore ISI
01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
ALXO ALX Oncology
$55.06 /

+4.22 (+8.30%)

11/04/21 Piper Sandler
ALX Oncology selloff after ASH abstract 'wholly misplaced,' says Piper Sandler
09/29/21 Stifel
ALX Oncology initiated with a Buy at Stifel
07/05/21 Piper Sandler
ALX Oncology update for ALX148 'incrementally positive,' says Piper Sandler
05/04/21 Credit Suisse
ALX Oncology assumed with an Outperform at Credit Suisse
CRSP Crispr Therapeutics
$94.11 /

+3.8 (+4.21%)

11/08/21 Goldman Sachs
Bluebird Bio downgraded to Sell from Neutral at Goldman Sachs
11/04/21 Raymond James
ASH abstracts justify Crispr Therapeutics concerns, says Raymond James
11/04/21 Oppenheimer
Crispr Therapeutics price target lowered to $172 from $185 at Oppenheimer
10/19/21 SVB Leerink
Crispr Therapeutics initiated with an Outperform at SVB Leerink
EHC Encompass Health
$65.05 /

+0.105 (+0.16%)

11/03/21 Mizuho
Encompass Health price target lowered to $80 from $94 at Mizuho
11/01/21 BMO Capital
Encompass Health price target lowered to $75 from $102 at BMO Capital
10/29/21 Deutsche Bank
Encompass Health price target lowered to $95 from $110 at Deutsche Bank
10/13/21 Truist
Encompass Health price target lowered to $88 from $100 at Truist
EFTR eFfector Therapeutics
$10.98 /

+0.6 (+5.78%)

10/12/21 Credit Suisse
eFfector Therapeutics initiated with an Outperform at Credit Suisse
10/04/21 Mizuho
eFfector Therapeutics initiated with a Buy at Mizuho
09/21/21 JMP Securities
eFfector Therapeutics initiated with an Outperform at JMP Securities
09/20/21 Stifel
eFfector Therapeutics initiated with a Hold at Stifel
CADL Candel Therapeutics
$11.48 /

+0.77 (+7.19%)

08/23/21 UBS
Candel Therapeutics initiated with a Buy at UBS
08/23/21 Jefferies
Candel Therapeutics initiated with a Buy at Jefferies
08/23/21 Credit Suisse
Candel Therapeutics initiated with an Outperform at Credit Suisse
CBAY CymaBay
$4.31 /

-0.08 (-1.82%)

08/18/21 B. Riley
CymaBay price target lowered to $10 from $13 at B. Riley
08/03/21 H.C. Wainwright
CymaBay price target lowered to $12 from $13 at H.C. Wainwright
08/02/21 Piper Sandler
CymaBay agreement removes 'key pressure point,' says Piper Sandler
06/21/21 Piper Sandler
Piper radar 'locked' on CymaBay EASL poster presentations on June 23
HSKA Heska
$197.45 /

+5.115 (+2.66%)

10/26/21 Alliance Global Partners
Alliance Global reiterates Buy on Heska, says short report lacks credibility
08/04/21 Alliance Global Partners
Heska price target raised to $310 from $240 at Alliance Global Partners
08/04/21 Piper Sandler
Heska price target raised to $305 from $240 at Piper Sandler
07/12/21 Guggenheim
Heska upgraded to Buy from Neutral at Guggenheim
VYGR Voyager Therapeutics
$3.72 /

-0.08 (-2.11%)

11/02/21 Chardan
Voyager Therapeutics price target lowered to $4 from $5.50 at Chardan
10/07/21 Baird
Voyager Therapeutics upgraded to Outperform from Neutral at Baird
10/06/21 Wells Fargo
Voyager platform validated by Pfizer agreement, says Wells Fargo
09/20/21 Benchmark
Sale of Voyager more likely than out-licensing, says Benchmark
CYT Cyteir Therapeutics
$17.14 /

+0.39 (+2.33%)

07/13/21 JPMorgan
Cyteir Therapeutics initiated with an Overweight at JPMorgan
07/13/21 BofA
BofA starts Cyteir Therapeutics at Buy with $23 price target
07/13/21 Wedbush
Cyteir Therapeutics initiated with an Outperform at Wedbush
07/13/21 Morgan Stanley
Cyteir Therapeutics initiated with an Overweight at Morgan Stanley
CYH Community Health
$14.55 /

+0.15 (+1.04%)

10/13/21 Truist
Community Health price target lowered to $12 from $14 at Truist
09/23/21 UBS
Community Health initiated with a Neutral at UBS
09/23/21 UBS
Community Health initiated with a Neutral at UBS
08/23/21 Truist
Community Health price target lowered to $14 from $17 at Truist
VYGR Voyager Therapeutics
$3.72 /

-0.08 (-2.11%)

VRDN Viridian Therapeutics
$18.12 /

-0.88 (-4.63%)

UTHR United Therapeutics
$200.75 /

-1.62 (-0.80%)

USPH U.S. Physical Therapy
$109.36 /

-0.05 (-0.05%)

HSKA Heska
$197.45 /

+5.115 (+2.66%)

EHC Encompass Health
$65.05 /

+0.105 (+0.16%)

EFTR eFfector Therapeutics
$10.98 /

+0.6 (+5.78%)

CYH Community Health
$14.55 /

+0.15 (+1.04%)

CRSP Crispr Therapeutics
$94.11 /

+3.8 (+4.21%)

CBAY CymaBay
$4.31 /

-0.08 (-1.82%)

CADL Candel Therapeutics
$11.48 /

+0.77 (+7.19%)

BAX Baxter
$78.84 /

+0.81 (+1.04%)

ALXO ALX Oncology
$55.06 /

+4.22 (+8.30%)

  • 21
    Sep
  • 27
    Jul
  • 18
    Jun
  • 03
    Mar
  • 13
    Jan
  • 10
    Dec
HSKA Heska
$197.45 /

+5.115 (+2.66%)

CYH Community Health
$14.55 /

+0.15 (+1.04%)

BAX Baxter
$78.84 /

+0.81 (+1.04%)

VRDN Viridian Therapeutics
$18.12 /

-0.88 (-4.63%)

UTHR United Therapeutics
$200.75 /

-1.62 (-0.80%)

HSKA Heska
$197.45 /

+5.115 (+2.66%)

EHC Encompass Health
$65.05 /

+0.105 (+0.16%)

EFTR eFfector Therapeutics
$10.98 /

+0.6 (+5.78%)

CYT Cyteir Therapeutics
$17.14 /

+0.39 (+2.33%)

CYH Community Health
$14.55 /

+0.15 (+1.04%)

CRSP Crispr Therapeutics
$94.11 /

+3.8 (+4.21%)

CADL Candel Therapeutics
$11.48 /

+0.77 (+7.19%)

BAX Baxter
$78.84 /

+0.81 (+1.04%)

ALXO ALX Oncology
$55.06 /

+4.22 (+8.30%)

VYGR Voyager Therapeutics
$3.72 /

-0.08 (-2.11%)

VRDN Viridian Therapeutics
$18.12 /

-0.88 (-4.63%)

EHC Encompass Health
$65.05 /

+0.105 (+0.16%)

CYH Community Health
$14.55 /

+0.15 (+1.04%)

CRSP Crispr Therapeutics
$94.11 /

+3.8 (+4.21%)

BAX Baxter
$78.84 /

+0.81 (+1.04%)

Hot Stocks
Baxter reveals data from Sharesource platform supporting home dialysis option » 08:40
11/08/21
11/08
08:40
11/08/21
08:40
BAX

Baxter

$78.04 /

-0.28 (-0.36%)

Baxter International…

Baxter International announced new data showing kidney patients may experience a survival rate nearly two-times higher and a prolonged time to an adverse event and hospitalization when the Sharesource remote patient management digital health platform is used to help manage home automated peritoneal dialysis .The new data was presented during the American Society of Nephrology's annual Kidney Week, Nov. 4-7, in abstract session, "Remote Monitoring of Patients with APD May Improve Clinical Outcomes: Analysis by Competing-Risk Regression Models,". The randomized controlled trial of 815 kidney patients spanning 22 hospitals in Mexico evaluated mortality and first AE or first hospitalization for kidney patients on home APD with and without the aid of remote patient management digital health. "The study indicates Sharesource's role in supporting clinically meaningful outcomes that help kidney patients gain access to home dialysis and remain on therapy for as long as possible," said Peter Rutherford, MB BS, PhD., vice president Medical Affairs, Baxter Renal Care. "As we move through the COVID-19 pandemic, digital health is demonstrating how it may support healthcare professionals to improve clinical outcomes and allow patients to remain at home with reduced unplanned hospital visits."

ShowHide Related Items >><<
BAX Baxter
$78.04 /

-0.28 (-0.36%)

BAX Baxter
$78.04 /

-0.28 (-0.36%)

11/05/21 Stifel
Hill-Rom downgraded to Hold from Buy at Stifel
10/28/21 Piper Sandler
Piper Sandler keeps a Neutral rating on Baxter following quarterly results
09/21/21 Raymond James
Baxter resumed with an Outperform at Raymond James
09/19/21 Morgan Stanley
Hill-Rom downgraded to Equal Weight from Overweight at Morgan Stanley
BAX Baxter
$78.04 /

-0.28 (-0.36%)

BAX Baxter
$78.04 /

-0.28 (-0.36%)

BAX Baxter
$78.04 /

-0.28 (-0.36%)

BAX Baxter
$78.04 /

-0.28 (-0.36%)

Downgrade
Hill-Rom downgraded to Hold from Buy at Stifel » 13:09
11/05/21
11/05
13:09
11/05/21
13:09
HRC

Hill-Rom

/

+

, BAX

Baxter

$78.12 /

-0.2 (-0.26%)

Stifel analyst Rick Wise…

Stifel analyst Rick Wise downgraded Hill-Rom (HRC) to Hold from Buy with a price target of $156, up from $155, after the company's CEO John Groetelaars indicated that the combination with Baxter (BAX) remains on track to close by "early 2022," as expected. In light of that potential transaction close and the stock's recent stock move towards the $156 deal price, he lowered his rating, Wise said.

ShowHide Related Items >><<
HRC Hill-Rom
/

+

BAX Baxter
$78.12 /

-0.2 (-0.26%)

HRC Hill-Rom
/

+

10/28/21 Piper Sandler
Piper Sandler keeps a Neutral rating on Baxter following quarterly results
09/21/21 Raymond James
Baxter resumed with an Outperform at Raymond James
09/19/21 Morgan Stanley
Hill-Rom downgraded to Equal Weight from Overweight at Morgan Stanley
09/07/21 KeyBanc
Hill-Rom downgraded to Sector Weight from Overweight at KeyBanc
BAX Baxter
$78.12 /

-0.2 (-0.26%)

09/13/21 Cowen
Baxter upgraded to Outperform from Market Perform at Cowen
HRC Hill-Rom
/

+

BAX Baxter
$78.12 /

-0.2 (-0.26%)

HRC Hill-Rom
/

+

HRC Hill-Rom
/

+

BAX Baxter
$78.12 /

-0.2 (-0.26%)

BAX Baxter
$78.12 /

-0.2 (-0.26%)

Over a month ago
Recommendations
Piper Sandler keeps a Neutral rating on Baxter following quarterly results » 15:45
10/28/21
10/28
15:45
10/28/21
15:45
BAX

Baxter

$78.53 /

-3.41 (-4.16%)

, HRC

Hill-Rom

$154.88 /

+0.3 (+0.19%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien notes Baxter (BAX) reported Q3 revenues that met expectations on the top-line and beat on the bottom-line. Management reaffirmed its full-year revenue projections but raised adjusted EPS expectations by eight cents, the analyst adds. The Q4 outlook implies sequential improvement to finish the year, yet falls slightly short of his estimates. O'Brien points out that management expects margins to be pressured going into 2022 despite ongoing work with cost containment and efficiency in the supply chain. Lastly, management expressed optimism about the recent Hillrom (HRC) acquisition and upcoming Novum IQ launch, both of which should benefit the top line over the coming years, he adds. While Baxter continues to deliver steady performance and has an "excellent management team at the helm," the lack of near-term catalysts keeps him on the sidelines. The analyst reiterates a Neutral rating and price target of $82 on the shares.

ShowHide Related Items >><<
HRC Hill-Rom
$154.88 /

+0.3 (+0.19%)

BAX Baxter
$78.53 /

-3.41 (-4.16%)

BAX Baxter
$78.53 /

-3.41 (-4.16%)

09/21/21 Raymond James
Baxter resumed with an Outperform at Raymond James
09/19/21 Morgan Stanley
Hill-Rom downgraded to Equal Weight from Overweight at Morgan Stanley
09/13/21 Cowen
Baxter upgraded to Outperform from Market Perform at Cowen
09/07/21 KeyBanc
Hill-Rom downgraded to Sector Weight from Overweight at KeyBanc
HRC Hill-Rom
$154.88 /

+0.3 (+0.19%)

09/03/21 Barclays
Barclays upgrades Baxter with $100 target after Hill-Rom deal
HRC Hill-Rom
$154.88 /

+0.3 (+0.19%)

BAX Baxter
$78.53 /

-3.41 (-4.16%)

BAX Baxter
$78.53 /

-3.41 (-4.16%)

HRC Hill-Rom
$154.88 /

+0.3 (+0.19%)

BAX Baxter
$78.53 /

-3.41 (-4.16%)

BAX Baxter
$78.53 /

-3.41 (-4.16%)

Earnings
Baxter sees Q4 EPS $1.00-$1.04, consensus $1.02 » 07:33
10/28/21
10/28
07:33
10/28/21
07:33
BAX

Baxter

$81.94 /

+0.125 (+0.15%)

For fourth-quarter 2021:…

For fourth-quarter 2021: The company expects sales growth of 3% to 4% on a reported basis, 4% to 5% on a constant currency basis and 3% to 4% on an operational basis. The company expects U.S. GAAP earnings of $0.75 to $0.79 per diluted share and adjusted earnings, before special items, of $1.00 to $1.04 per diluted share.

ShowHide Related Items >><<
BAX Baxter
$81.94 /

+0.125 (+0.15%)

BAX Baxter
$81.94 /

+0.125 (+0.15%)

09/21/21 Raymond James
Baxter resumed with an Outperform at Raymond James
09/19/21 Morgan Stanley
Hill-Rom downgraded to Equal Weight from Overweight at Morgan Stanley
09/13/21 Cowen
Baxter upgraded to Outperform from Market Perform at Cowen
09/07/21 KeyBanc
Hill-Rom downgraded to Sector Weight from Overweight at KeyBanc
BAX Baxter
$81.94 /

+0.125 (+0.15%)

BAX Baxter
$81.94 /

+0.125 (+0.15%)

BAX Baxter
$81.94 /

+0.125 (+0.15%)

BAX Baxter
$81.94 /

+0.125 (+0.15%)

Earnings
Baxter sees FY21 EPS $3.58 to $3.62, consensus $3.52 » 07:30
10/28/21
10/28
07:30
10/28/21
07:30
BAX

Baxter

$81.94 /

+0.125 (+0.15%)

For full-year 2021,…

For full-year 2021, Baxter now expects U.S. GAAP earnings of $2.82 to $2.86 per diluted share and adjusted earnings, before special items, of $3.58 to $3.62 per diluted share. The company expects sales growth of 7% to 8% on a reported basis, 5% to 6% on a constant currency basis and 4% to 5% on an operational basis.

ShowHide Related Items >><<
BAX Baxter
$81.94 /

+0.125 (+0.15%)

BAX Baxter
$81.94 /

+0.125 (+0.15%)

09/21/21 Raymond James
Baxter resumed with an Outperform at Raymond James
09/19/21 Morgan Stanley
Hill-Rom downgraded to Equal Weight from Overweight at Morgan Stanley
09/13/21 Cowen
Baxter upgraded to Outperform from Market Perform at Cowen
09/07/21 KeyBanc
Hill-Rom downgraded to Sector Weight from Overweight at KeyBanc
BAX Baxter
$81.94 /

+0.125 (+0.15%)

BAX Baxter
$81.94 /

+0.125 (+0.15%)

BAX Baxter
$81.94 /

+0.125 (+0.15%)

BAX Baxter
$81.94 /

+0.125 (+0.15%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.